2024-02-26 17:03:21 ET
In 2023, Gilead's total revenues decreased by 1% due to lower Veklury sales, offset by higher HIV and Oncology sales. Net income rose to $5.7 billion, with diluted earnings per share at $4.50. Management focuses on leadership development and mitigating cybersecurity risks. Key performance indicators show positive growth, with plans for expansion. Risks include currency exchange and legal actions. Corporate governance emphasizes diversity and sustainability. Forward guidance aligns with strategic ... Full story available on KlickAnalytics.com